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KRYSIA LESNIAK

(Pharmacy)

Promoting Adult Pneumococcal Vaccinations Through Pharmacy and
Provider Educational Campaigns
Sponsor: Brett Feret (PharmD)

Pneumococcal disease refers to any infection caused by Streptococcus pneumoniae,
ranging from ear and sinus infections to pneumonia and infections of the bloodstream
(bacteremia). In the United States, pneumococcal pneumonia caused an estimated
150,000 hospitalizations, while pneumococcal meningitis and bacteremia resulted in
3,250 deaths in 2019. Vaccination is the most effective way of preventing pneumococcal
disease, of which there are two kinds: pneumococcal conjugate vaccines (PCV13,
PCV15, or PCV20) and pneumococcal polysaccharide vaccine (PPSV23). Overall
pneumococcal vaccination coverage among adults aged 19-64 years at increased risk for
disease was 23.3% in 2018, and that of adults aged ≥ 65, those at the greatest risk of
serious illness and death, was 69%.
Six Doctor of Pharmacy students from the University of Rhode Island were trained to
provide academic detailing to community pharmacists throughout Massachusetts and
Rhode Island. These sessions encouraged immunization providers to utilize a clinical
pathway to determine patients’ pneumococcal vaccine eligibility. The interprofessional
academic detailing was well-received; of the 65 community-based pharmacists educated,
89.2% strongly agreed or agreed that their knowledge of the PCV13 and PPSV23
vaccines had improved. A total of 93.8% respondents agreed that they felt confident and
intend on applying this knowledge in clinical practice. This work provides additional
insight on the potential of effective academic outreach to enhance vaccination practice
and improve patient outcomes.
Following the success with community pharmacists, ambulatory care pharmacists of
Rhode Island Primary Care Physicians Corporation were educated on the two new
pneumococcal vaccines (PCV15 and PCV20) per the latest recommendations from the
Advisory Committee on Immunization Practices (ACIP). Both PCV15 and PCV20 broaden
the serotype coverage of pneumococcal conjugate vaccines, and PCV20 offers a single
vaccine option that is expected to provide cost-savings and better protection. Importantly,
PCV15 and PCV20 streamline pneumococcal vaccine eligibility and simplify the process
of determining who is eligible receive a vaccine. With pharmacists interacting with
patients at an increased risk for serious illness daily, we are hopeful that this education
will further improve adult vaccination rates in the community.
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